A pharmaceutical composition and its application in preparing a drug for treating non-small cell lung cancer
Through the composition of yamphetamine and EGFR-TKI, the problem of EGFR-TKI in the treatment of non-small cell lung cancer was solved, and the effect of reversing drug resistance and enhancing efficacy was achieved, which significantly improved the inhibitory ability of drug-resistant cells and Reduced drug concentration requirements.
Patent Information
- Application Number
- CN202411268667.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-09-11
AI Technical Summary
Existing EGFR-TKI drugs are prone to drug resistance problems in the treatment of non-small cell lung cancer, resulting in reduced efficacy and lack of effective reverse drug resistance strategies.
The combination of yamphetamine and EGFR-TKI (such as osimertinib) is used to reverse EGFR-TKI resistance through synergistic action to enhance the efficacy of treating non-small cell lung cancer.
The combination of yamophenol and EGFR-TKI significantly increased the inhibitory rate of drug-resistant lung cancer cells, reduced the need for drug concentration, reduced the side effects of targeted drugs, and significantly enhanced the therapeutic effect.
Smart Images

Figure CN118767145B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of medicine, and in particular to a pharmaceutical composition and application thereof in preparing an anti-non-small cell lung cancer drug. Background Art
[0002] Globally, the number of lung cancer cases and deaths is still increasing year by year. The GLOBOCAN database shows that in 2020, there were 19.3 million new cancer cases and nearly 10 million cancer deaths worldwide, among which the incidence of lung cancer ranked second (11.4%) and was the main cause of cancer death. Lung cancer is divided into different histological subtypes, including adenocarcinoma, squamous cell carcinoma, large cell carcinoma (commonly known as non-small cell lung cancer, NSCLC) and small cell lung cancer (small cell lung cancer, SCLC). Among them, about 80-85% are NSCLC. Since there are no typical symptoms in the early stage of the disease, nearly 70% of NSCLC patients are already in the middle and late stages when diagnosed. Not only have they lost the opportunity for surgery, but they are also insensitive to conventional chemotherapy and radiotherapy, and the 5-year survival rate is only about 15%. The occurrence of NSCLC includes changes in genes such as EGFR, KRAS and BRAF. Studies have found that nearly 50% of Asian patients with advanced non-small cell lung cancer have activating mutations in the EGFR gene in the tyrosine kinase domain. Therefore, the use of small molecule EGFR tyrosine kinase inhibitors (EGFR-TKIs) as targeted therapy has changed the course of EGFR-mutant lung cancer.
[0003] Osimertinib is a monoaniline pyrimidine compound that works by irreversibly inhibiting the EGFR kinase domain and T790M mutation. As a third-generation EGFR-TKI, it is mainly used to treat metastatic non-small cell lung cancer with EGFR mutations, and can significantly prolong the survival of patients who develop resistance to first- and second-generation EGFR-TKIs. Although the efficacy of osimertinib in first- and second-line settings is well documented, patients still inevitably develop resistance. In order to overcome osimertinib resistance and enhance its efficacy, in addition to the fourth-generation EGFR-TKI currently under development for the EGFR-C797S mutation, finding strategies to reverse osimertinib resistance and exploring combination therapy options have become hot topics in current research.
[0004] Kaempferol is a flavonoid compound in the form of aglycones, which is found in different parts of plants, such as seeds, leaves, fruits, flowers, and even vegetables. Kaempferol has various pharmacological effects, such as cardioprotective, neuroprotective, anti-inflammatory, antidiabetic, antioxidant, antimicrobial, antitumor, and anticancer activities. Epidemiological studies have shown that high intake of kaempferol is closely associated with a reduced incidence of different types of cancer, including skin cancer, liver cancer, colon cancer, ovarian cancer, pancreatic cancer, gastric cancer, and bladder cancer. However, to date, there have been no reports on the combination of kaempferol and EGFR-TKI drugs for the treatment of non-small cell lung cancer. Summary of the invention
[0005] In order to overcome the defects of the prior art, the technical problem to be solved by the present invention is to provide a pharmaceutical composition which can have a synergistic effect, can reverse EGFR-TKI resistance, and increase the effect of EGFR-TKI in treating non-small cell lung cancer.
[0006] The technical scheme of the present invention is: the active ingredients of the pharmaceutical composition include kaempferol and epidermal growth factor receptor tyrosine kinase inhibitor EGFR-TKI;
[0007] The structural formula of the kaempferol is:
[0008] ;
[0009] The EGFR-TKI is one of gefitinib, erlotinib, afatinib, or osimertinib.
[0010] The beneficial effects of the present invention are: it can have a synergistic effect, can reverse EGFR-TKI resistance, and increase the effect of EGFR-TKI in treating non-small cell lung cancer.
[0011] Also provided is the use of the pharmaceutical composition in preparing an anti-non-small cell lung cancer drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 To investigate the effects of different substances combined with osimertinib on the proliferation of osimertinib-resistant lung cancer cells.
[0013] Figure 2 To examine the effects of kaempferol or osimertinib alone on the viability of osimertinib-acquired resistance lung cancer cells. Figure 2 A shows the cell survival rate of PC-9, A549 or NCI-H1975 cells after 24 h of kaempferol treatment. Figure 2 B shows osimertinib treatment of PC-9 del19-T790M-C797S IC50 value of cells at 24h. Figure 2 C shows kaempferol-treated PC-9 del19-T790M-C797S IC50 value of cells at 24h. Figure 2 D shows osimertinib combined with kaempferol treatment of PC-9 del19-T790M-C797S IC50 value of cells at 24h.
[0014] Figure 3 To investigate the effect of kaempferol combined with osimertinib on osimertinib-acquired resistance in PC-9 cells by cell scratch assay. del19-T790M-C797S Effects on cell migration ability.
[0015] Figure 4 To investigate the effects of kaempferol alone or in combination with osimertinib on osimertinib-acquired resistance in PC-9 cells by Transwell assay. del19-T790M-C797S Effects on cell migration ability.
[0016] Figure 5 To investigate the effect of kaempferol alone or in combination with osimertinib on osimertinib-acquired resistance in PC-9 cells by using a 3D tumor cell spheroid assay. del19-T790M-C797S Effect of cell spheroidization ability. DETAILED DESCRIPTION
[0017] The active ingredients of the pharmaceutical composition include kaempferol and an epidermal growth factor receptor tyrosine kinase inhibitor EGFR-TKI;
[0018] The structural formula of the kaempferol is:
[0019] ;
[0020] The EGFR-TKI is one of gefitinib, erlotinib, afatinib, or osimertinib.
[0021] The beneficial effects of the present invention are: it can have a synergistic effect, can reverse EGFR-TKI resistance, and increase the effect of EGFR-TKI in treating non-small cell lung cancer.
[0022] Preferably, the concentrations of kaempferol and EGFR-TKI are the same.
[0023] Preferably, the EGFR-TKI is osimertinib.
[0024] Preferably, the pharmaceutical composition is in the form of oral tablets, capsules, or injections.
[0025] Also provided is the use of the pharmaceutical composition in preparing an anti-non-small cell lung cancer drug.
[0026] Preferably, the pharmaceutical composition inhibits A549, PC-9, H1975 cells and PC-9 del19-T790M-C797S Cell proliferation activity. PC-9 del19-T790M-C797S It is an osimertinib-resistant cell line.
[0027] Preferably, the pharmaceutical composition inhibits PC-9 del19-T790M-C797S Cell clone formation.
[0028] Preferably, the pharmaceutical composition inhibits PC-9 del19-T790M-C797S Migration of cells.
[0029] Preferably, the pharmaceutical composition inhibits PC-9 del19-T790M-C797S The size and number of cell spheres.
[0030] The embodiments of the present invention are described in detail below.
[0031] Experimental Example 1
[0032] Tumor cell proliferation experiments were performed using the CCK-8 assay, and the effects of combined use of emodin, quercetin, baicalin, curcumin, catechins, oleanolic acid, schisandrin, kaempferol, and kaempferol with osimertinib on the proliferation of osimertinib-resistant lung cancer cells were screened.
[0033] PC-9 del19-T790M-C797S Cells were purchased from Nanjing Kebai Biotechnology Co., Ltd.; rhubarb, quercetin, baicalin, curcumin, catechin, oleanolic acid, puerarin, schisandrin, kaempferol, and kaempferol were purchased from the National Institute of Food and Drug Control; and osimertinib was purchased from MCE.
[0034] Take PC-9 in logarithmic growth period del19-T790M-C797S Cells were seeded in 96-well plates (8000 cells / well) and cultured for 24 hours. After the cells adhered to the wall, 10 μM emodin, quercetin, baicalein, curcumin, catechin, oleanolic acid, puerarin, schisandrin, kaempferol, kaempferol (the solvent was DMSO) and osimertinib (1 μM) were added for combined administration. After 24 hours of treatment at 37°C and 5% carbon dioxide, 10% CCK-8 solution was added to each well, and the culture plate was placed in an incubator for further incubation for 1-4 hours. The absorbance at 450 nm was measured by a microplate reader, and the cell survival rate (%) of each group was calculated = (absorbance of the experimental group - absorbance of the blank group) / (absorbance of the control group - absorbance of the blank group) × 100%.
[0035] The results are as follows Figure 1 The results showed that compared with other flavonoid Chinese medicines, kaempferol and kaempferol have better effects in reversing osimertinib resistance and synergistically enhancing the effect against non-small cell lung cancer; among them, kaempferol has the best synergistic effect in reversing osimertinib resistance.
[0036] Experimental Example 2
[0037] Tumor cell proliferation experiments were performed using CCK-8 experiments to compare the effects of kaempferol and osimertinib alone and in combination on the proliferation of common lung cancer cells or osimertinib-resistant lung cancer cells.
[0038] A549, PC-9 and H1975 cells were purchased from Wuhan Pronocell Life Science Co., Ltd.; PC-9 del19-T790M-C797S Cells were purchased from Nanjing Kebai Biotechnology Co., Ltd.; kaempferol was purchased from the National Institutes for Food and Drug Control; and osimertinib was purchased from MCE.
[0039] (1) The CCK-8 method was used to detect the effect of kaempferol on the viability of different common lung cancer cells. Specifically:
[0040] A549, PC-9 or NCI-H1975 cells in the logarithmic growth phase were inoculated in 96-well plates (8000 cells / well), cultured for 24 hours, and then 10 μM kaempferol (solvent: DMSO) was added after the cells adhered to the wall. After treatment at 37°C and 5% carbon dioxide for 24 hours, 10% CCK-8 solution was added to each well, and the culture plate was placed in an incubator for further incubation for 1-4 hours. The absorbance at 450 nm was measured by a microplate reader, and the survival rate of each cell (%) was calculated as (absorbance of the experimental group - absorbance of the blank group) / (absorbance of the control group - absorbance of the blank group) × 100%.
[0041] The results are as follows Figure 2 A shows that after kaempferol treatment of PC-9, A549 or NCI-H1975 cells for 24 hours, the cell viability rates were 67.55%, 76.12% and 47.25%, respectively.
[0042] (2) CCK-8 assay was used to detect the effects of kaempferol or osimertinib alone on the viability of osimertinib-acquired drug-resistant lung cancer cells.
[0043] Take PC-9 in logarithmic growth period del19-T790M-C797S Cells were seeded in 96-well plates (8000 cells / well) and cultured for 24 hours. After the cells adhered to the wall, different concentrations of kaempferol or osimertinib (solvent: DMSO) were added. After treatment at 37°C and 5% carbon dioxide for 24 hours, 10% CCK-8 solution was added to each well. The culture plates were placed in an incubator and incubated for 1-4 hours. The absorbance at 450 nm was measured by a microplate reader, and the IC50 value was calculated.
[0044] The results showed that osimertinib treated PC-9 del19-T790M-C797S The IC50 value of the cells for 24 h was 1.587 mM (see Figure 2 B), while kaempferol treated PC-9 del19-T790M-C797SThe IC50 value of the cells for 24 h was 0.579 mM (see Figure 2 C).
[0045] (3) CCK-8 method was used to detect the effect of kaempferol combined with osimertinib on the viability of osimertinib-acquired drug-resistant lung cancer cells. Specifically:
[0046] Take PC-9 in logarithmic growth period del19-T790M-C797S Cells were seeded in 96-well plates (8000 cells / well) and cultured for 24 hours. After the cells adhered to the wall, different concentrations of kaempferol and osimertinib were added. After 24 hours of treatment at 37°C and 5% carbon dioxide, 10% CCK-8 solution was added to each well. The culture plates were placed in an incubator and incubated for 1-4 hours. The absorbance at 450 nm was measured by a microplate reader, and the IC50 value and cell survival rate of each group (%) were calculated = (absorbance of the experimental group - absorbance of the blank group) / (absorbance of the control group - absorbance of the blank group) × 100%.
[0047] The results are as follows Figure 2 D and Table 1 show that kaempferol combined with osimertinib has an effective effect on PC-9 del19-T790M-C797S The cell inhibition rate was significantly higher than that of the single drug group. 50 The value was 0.484 nM. The combined effect of osimertinib and kaempferol on PC-9 del19 -T790M-C797S The cells have a synergistic inhibitory effect.
[0048] Table 1. PC-9 after administration del19-T790M-C797S Cell viability
[0049]
[0050] The present invention found that the inhibition rate of osimertinib-resistant cells by kaempferol combined with osimertinib was significantly higher than that of the single drug group, and there was a significant synergistic effect. The combination scheme has the potential to reduce the effective drug concentration and reduce the side effects caused by the high-dose use of targeted drugs.
[0051] Experimental Example 3
[0052] Cell scratch assay to detect the effect of kaempferol combined with osimertinib on osimertinib-acquired resistance PC-9 del19-T790M-C797S The specific experimental steps are as follows:
[0053] Take PC-9 in logarithmic growth period del19-T790M-C797SCells were seeded in 96-well plates (8000 cells / well) and cultured for 48 h until the cells adhered to the wall and grew confluently. The bottom of the culture wells was scratched with a streaker, the culture supernatant was aspirated, and the cells were washed 2-3 times with PBS. Then, the culture medium containing kaempferol, osimertinib, or the combination of kaempferol and osimertinib was added and incubated at 37°C and 5% CO. 2 The cells were cultured under the same conditions. Samples were taken at 0h, 24h, and 48h, and photos were taken to observe the changes in cell migration.
[0054] The results are as follows Figure 3 Compared with the osimertinib group alone, kaempferol combined with osimertinib significantly inhibited PC-9 del19-T790M-C797S Cell migration ability.
[0055] Experimental Example 4
[0056] Transwell assay was used to detect the effects of kaempferol alone or in combination with osimertinib on osimertinib-acquired resistance in PC-9 cells del19-T790M-C797S Effects on cell migration ability.
[0057] Transwell chamber was purchased from Corning (Cat. No. 3422).
[0058] The specific experimental steps are as follows: del19-T790M-C797S Cells were seeded in 6-well plates (2×10 5 Cells / well) were added 24 h later. Solvent DMSO (blank control group), 10 nM kaempferol, 1.5 μM osimertinib, and combination drugs (10 nM kaempferol, 1.5 μM osimertinib) were added. After 48 h, the cells were transferred to the upper chamber of the Transwell chamber of a 24-well plate (2×10 4 500 μL of 1640 medium containing 10% FBS was added to the lower chamber, and after culturing for 24 h, 4% paraformaldehyde was added for fixation for 15 min, and 0.1% crystal violet was added for staining at room temperature for 15 min. The cells were photographed under a microscope and counted using Image J software.
[0059] The results are as follows Figure 4 Compared with the blank control group and the osimertinib group, the PC-9 del19-T790M-C797S The above results show that the combination of kaempferol and osimertinib can significantly inhibit PC-9 del19-T790M-C797S Cell migration ability of cells.
[0060] Experimental Example 5
[0061] The effects of kaempferol alone or in combination with osimertinib on osimertinib-acquired resistance PC-9 cells were detected by 3D tumor cell spheroidization assay.del19-T790M-C797S Effect of cell spheroidization ability.
[0062] StemXVivo serum-free tumor sphere culture medium was purchased from R&D Systems (Cat. No.: CCM012); ultra-low attachment 96-well plates were purchased from Corning (Cat. No.: 3474).
[0063] The specific experimental steps are as follows: del19-T790M-C797S Cells were seeded in 6-well plates (2×10 5 Cells were added to the cells at 400 μg / well. After 24 h, DMSO (blank control group), 10 nM kaempferol, 1.5 μM osimertinib, and combination drugs (10 nM kaempferol, 1.5 μM osimertinib) were added. After 48 h, the cells were resuspended and diluted in serum-free tumor sphere culture medium and transferred to ultra-low adsorption 96-well plates at a number of 500 cells per well. After 14 days of culture, the formation of tumor spheres was observed under a microscope.
[0064] The results are as follows Figure 5 The results showed that compared with the blank control group and the osimertinib group alone, the combined drug regimen could significantly inhibit PC-9 del19-T790M-C797S The above is only a preferred embodiment of the present invention, and does not limit the present invention in any form. Any simple modification, equivalent change and modification made to the above embodiment according to the technical essence of the present invention still belongs to the protection scope of the technical solution of the present invention.
Claims
1. Use of a pharmaceutical composition in the preparation of an anti-non-small cell lung cancer drug, characterized in that: The active ingredients of the pharmaceutical composition are kaempferol and osimertinib; The structural formula of the kaempferol is: ; The molar ratio of kaempferol to osimertinib is 10:1; and the application is to produce synergistic enhancement in non-small cell lung cancer cells.
2. Use of the pharmaceutical composition according to claim 1 in the preparation of an anti-non-small cell lung cancer drug, characterized in that: The pharmaceutical composition is in the form of oral tablets, capsules, or injections.
3. Use of the pharmaceutical composition according to claim 2 in the preparation of an anti-non-small cell lung cancer drug, characterized in that: It inhibits A549, PC-9, H1975 cells and PC-9 del19-T790M-C797S Cell proliferation activity.
4. Use of the pharmaceutical composition according to claim 2 in the preparation of an anti-non-small cell lung cancer drug, characterized in that: It inhibits PC-9 del19-T790M-C797S Cell clone formation.
5. Use of the pharmaceutical composition according to claim 2 in the preparation of an anti-non-small cell lung cancer drug, characterized in that: It inhibits PC-9 del19-T790M-C797S Migration of cells.
6. Use of the pharmaceutical composition according to claim 2 in the preparation of an anti-non-small cell lung cancer drug, characterized in that: It inhibits PC-9 del19-T790M-C797S The size and number of cell spheres.
Citation Information
Patent Citations
Application of traditional Chinese medicine composition in preparation of antitumor drugs
CN115414399A
Pharmaceutical composition and application thereof in preparation of antitumor drugs
CN118059108A
